SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.
about
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-AnalysisMolecular markers of paragangliomas/pheochromocytomasP.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization.Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitroUrinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations.The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomasFamiliar Papillary Thyroid Carcinoma in a Large Brazilian Family Is Not Associated with Succinate Dehydrogenase Defects.Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?Inhibitors of succinate: quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death.Pheochromocytomas and paragangliomas: assessment of malignant potential.Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors.Orbital Paraganglioma and Succinate Dehydrogenase Staining for Genetic Testing Triage and Prognosis.SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).Down-regulation of succinate dehydrogenase subunit B and up-regulation of pyruvate dehydrogenase kinase 1 predicts poor prognosis in recurrent nasopharyngeal carcinoma.Usefulness of Negative and Weak–Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas
P2860
Q26749393-A3F89653-E0B5-424A-BFA6-CC19DAF01774Q33649025-0A37399B-2024-4BF8-8689-C0BA0ACD06D3Q34692517-4816490B-DA43-4F4F-8161-B75F00270D0AQ34787604-057B3894-16BC-437B-A3A4-A260972CF9A0Q36163643-765FE032-F2FA-4B1F-BE53-5584EB4A1474Q36473314-7D5483A9-F8A6-4548-805A-CCCE8646CFA8Q36594111-4FDC15B3-2C86-4B56-9EC8-07805C8CF7A0Q36804496-95DBEF6B-89E7-46C8-85F4-2F7609CA8BFEQ37104810-38FCD394-7F20-4312-B0C5-83811095F709Q37202015-0C099808-71B5-4DFE-BE35-70198130271EQ37701667-4DCC8B59-A306-4123-8332-13A082098632Q37882392-DE0B26D9-997B-4426-9875-76F503C7A977Q37921677-FFE74136-3BCC-4A52-91D8-53E7AC7B964BQ37950920-9DAB548C-FE82-4109-A8D1-B9A448356392Q37962361-6D26C564-2EAC-461D-B793-78B67EFCCED6Q37990768-77962AE4-B317-41A7-B1AA-5414AA5DCACBQ39164389-D5FA91E2-9856-4CD2-BD18-583001416180Q39644661-E390EE26-6D0A-485C-91EB-BF99CC145085Q40709867-D114CD29-D507-4FB6-B84D-C95E2D160B42Q48221255-60B4A76C-F4FF-49C5-BC0B-2B827A60D0E9Q53291423-032A9F31-4CC8-4784-9F85-6A2361A80752Q59123110-8171ABA7-80D8-43F8-8F6B-1F396191B28F
P2860
SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@en
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@nl
type
label
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@en
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@nl
prefLabel
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@en
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@nl
P2093
P356
P1476
SDHB loss predicts malignancy ...... ot through hypoxia signalling.
@en
P2093
Anja M Schmitt
Annika Blank
Esther Korpershoek
Francien van Nederveen
Nicole Weber
Paul Komminoth
Ronald de Krijger
Räto Thomas Strebel
Thomas Rudolph
P304
P356
10.1677/ERC-09-0316
P50
P577
2010-10-05T00:00:00Z